Arcellx, Inc. - Common Stock (NQ:ACLX)

115.07 UNCHANGED

Last Price Updated: 4:15 PM EDT, Apr 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know ↗

January 04, 2024

Via Benzinga

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗

December 15, 2023

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

Via InvestorPlace

Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 12, 2023

Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results.

Via Benzinga

Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say ↗

December 11, 2023

Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or

Via Benzinga

Where Arcellx Stands With Analysts ↗

December 11, 2023

Via Benzinga

Analyst Ratings for Arcellx ↗

June 20, 2023

Via Benzinga

Why Arcellx (ACLX) Stock Is Nosediving ↗

June 20, 2023

Arcellx Inc (NASDAQ: ACLX) shares are trading lower by 8.50% to $32.76 Tuesday morning after the FDA on Monday put a clinical hold on the company's multiple myeloma phase 2 trial.

Via Benzinga

Chart Of The Day: Arcellx - Reimagining Cell Therapy ↗

December 08, 2023

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.

Via Talk Markets

3 Biotech Stocks That Could Be Multibaggers in the Making ↗

November 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Via InvestorPlace

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead ↗

November 15, 2023

The companies will work together on treatments for multiple myeloma and lymphomas.

Via Investor's Business Daily

Kite and Arcellx Announce Expansion in Strategic Partnership

November 15, 2023

From Gilead Sciences, Inc.

Via Business Wire

Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today? ↗

November 02, 2023

Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refra

Via Benzinga

The Latest Analyst Ratings for Arcellx ↗

May 18, 2023

Via Benzinga

Where Arcellx Stands With Analysts ↗

April 24, 2023

Via Benzinga

Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

November 02, 2023

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.

Via Benzinga

Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday ↗

November 02, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

7 Biotech Stocks to Get In Now Before Investors Catch On ↗

October 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

Via InvestorPlace

Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs ↗

October 02, 2023

CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential ↗

August 15, 2023

The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program.

Via Benzinga

FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study ↗

August 15, 2023

The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 14, 2023

Via Benzinga

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death ↗

June 20, 2023

A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex.

Via Investor's Business Daily

Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls ↗

June 20, 2023

The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for

Via Benzinga

Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 20, 2023

Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.

Via Benzinga

Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗

June 20, 2023

Gainers

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

June 20, 2023

It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning!

Via InvestorPlace

Alibaba, Arcellx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

June 20, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗

May 18, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023 ↗

April 14, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.